Dual Targeting of the Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor Pathways with Vandetinib (ZD6474) in Patients with Advanced or Metastatic Non-small Cell Lung Cancer  by Natale, Ronald B.
NOVEL AGENTS IN THE TREATMENT OF LUNG CANCER
Dual Targeting of the Vascular Endothelial Growth Factor
Receptor and Epidermal Growth Factor Receptor Pathways
with Vandetinib (ZD6474) in Patients with Advanced or
Metastatic Non-small Cell Lung Cancer
Ronald B. Natale, MD
Vandetinib is a novel, selective dual inhibitor of the vascular
endothelial growth factor receptor pathway and epidermal growth
factor receptor pathway. Phase I studies have established that it is
suitable for once-daily oral dosing at a dose of up to 300 mg.
Vandetinib has been tested in multiple randomized controlled phase
II clinical studies, which have established that this is a promising
new targeted agent for the treatment of patients with advanced
non-small cell lung cancer and which also support the potential role
of vandetinib administered concurrently with chemotherapy. Further
testing of its role in lung cancer is in ongoing.
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Vandetinib (Zactima, ZD6474, AstraZeneca, Wilmington,Delaware) is a novel, selective inhibitor of vascular endo-
thelial growth factor receptors (VEGFRs) 2 and 3, epidermal
growth factor receptor (EGFR), and RET kinases. In preclin-
ical studies, it was found to be a potent inhibitor of tumor-
induced angiogenesis and of the growth of multiple epithelial
tumor models, including Calu-6 (lung), PC-3 (prostate),
LoVo (colon), MDA-MB-231 (breast), SKOV-3 (ovarian),
and A431 (vulva).1 More extensive laboratory studies in
human lung cancer cell line models demonstrated that van-
detinib is comparable to other EGFR inhibitors, including
gefitinib(Iressa, AstraZeneca, Wilmington, Delaware) and
erlotinib (Tarceva, Genentech, South San Francisco, CA) in
causing regression of established HCC827 xenografts.2 Nev-
ertheless, in contrast to gefitinib and erlotinib, vandetinib also
was effective in cell lines with acquired resistance to EGFR
inhibition (T790M mutation) and in cell lines with overex-
pression of K-ras.
Two phase I clinical trials with vandetinib established
that daily oral doses up to 300 mg were generally well
tolerated, with the most common adverse events consisting of
mild to moderate rash, diarrhea, and asymptomatic QTc
prolongation.3,4 Pharmacokinetic studies4 indicated a termi-
nal half-life of approximately 120 hours, which was suitable
for a once-daily oral dosing schedule. In the study by Tamura
et al.,4 the observation of objective responses in four of nine
Japanese patients with advanced non-small cell lung cancer
(NSCLC) suggested single-agent efficacy but also raised the
logical question of whether this new agent was acting simply
as another EGFR inhibitor or whether VEGFR inhibition
contributed to its efficacy. Furthermore, since the concurrent
use of EGFR inhibitors and chemotherapy has not been an
effective strategy thus far, the question remains of whether
this novel dual inhibitor will suffer the same dilemma.
The first phase II studies were designed to answer these
questions. Trial 3 was a phase II, randomized, double-blind
comparison of vandetinib and gefitinib in previously treated
patients with advanced or metastatic NSCLC (Figure 1).
After disease progression to the initial randomized treatment
(part A) and a 4-week no treatment washout, patients were
eligible to receive the alternate treatment in a blinded manner
(part B). Part A of the study was designed to have a 75%
power to detect a 33% increase in progression-free survival at
a significance level of p  0.02. Part B was designed to
obtain data regarding cross-resistance. Eligibility criteria in-
cluded patients with disease progression after first-line plat-
inum-based chemotherapy and not more than one additional
cytotoxic second-line regimen, a performance status of 0 to 2,
adequate organ function, and no prior exposure to an EGFR-
targeted agent. One hundred sixty-eight patients were entered
into part A of the study. The two arms were well balanced
with respect to median age, sex, performance status, smoking
history, histologic subtype, and stage IIIB versus stage IV.
The trial achieved its primary end point. Patients in the
vandetinib arm achieved a statistically significant improve-
ment in progression-free survival compared with the gefitinib
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arm with a hazard ratio of 0.69 (95% confidence interval,
0.50–0.96) and a 2-sided p value of 0.025. In part B of the
study, vandetinib achieved disease control in 16 of 37 pa-
tients (43%) who were initially treated with gefitinib. In
contrast, gefitinib achieved disease control in only 7 of 29
patients (24%) initially treated with vandetinib.
Rash, diarrhea, and nausea were similar in the two arms
of the study in part A and were generally mild. Headache,
dizziness, hypertension, and QT-related events were more
common in the vandetinib arm than in the gefitinib arm.
Trial 6 consisted of a run-in feasibility study of do-
cetaxel combined with vandetinib followed by a 3-armed
phase II randomized trial of docetaxel, 75 mg/m2 every 3
weeks alone or combined with 100 mg per day or 300 mg per
day of vandetinib5 (Figure 2). Eligibility criteria were similar
to trial 3 except patients may have received only first-line
platinum-based chemotherapy. Progression-free survival was
again the primary study end point. One hundred twenty-seven
patients were entered into the trial. Both vandetinib arms
produced an improvement in progression-free survival com-
pared with the docetaxel control arm, but only the 100-mg
dose level of vandetinib combined with docetaxel achieved
the study end point, with a hazard ratio of 0.64 (95% confi-
dence interval, 0.38–1.05). Adverse effects, including rash,
diarrhea, nausea or vomiting, hypertension, and QT-related
events, were mildly increased in the 100 mg of vandetinib
plus docetaxel arm compared with docetaxel alone (40%
versus 24%, 38% versus 27%, 31% versus 24%, 7% versus
2%, and 12% versus 5%, respectively) and moderately to
unacceptably increased in the 300 mg of vandetinib plus
docetaxel arm (46%, 50%, 34%, 9%, and 16%, respectively).
These two trials establish that vandetinib is a promising
new targeted agent for the treatment of patients with ad-
vanced NSCLC. Trial 3 confirms the single-agent activity of
this agent and that its efficacy is at least partly mediated
through its VEGR inhibitory property. Combined EGFR and
VEGFR inhibition with vandetinib produced a better progres-
sion-free survival compared with EGFR inhibition alone with
gefitinib. The fact that the disease control rate in part B of the
study was greater with vandetinib after gefitinib than it was
with gefitinib after vandetinib suggests that the improved
effectiveness of vandetinib in part A of the study derived, at
least in part, from its VEGFR inhibition. The reduced activity
of gefitinib after vandetinib in part B compared with gefitinib
in vandetinib-naive patients in part A strongly suggests that
vandetinib is an effective EGFR inhibitor as well. These
observations are currently under investigation in a definitive,
prospective, randomized, double-blind, international clinical
trial of vandetinib versus erlotinib.
Trial 6 strongly supports the potential role of vandetinib
administered concurrently with chemotherapy. Not only was
toxicity reduced at the 100-mg dose compared with the
FIGURE 1. Trial 3 Schema: Vandetanib versus
Gefitinib in a Randomized, Double-blind, Two-
part, multicenter study.
FIGURE 2. Trial 6 Schema: Vandetinib plus Do-
cetaxel versus Docetaxel in a Randomized, Dou-
ble-blind, Two-part, multicenter study.
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300-mg dose of vandetinib combined with docetaxel, but the
response rate and progression-free survival were somewhat
better as well. Although not proven by this study, this
differential effect suggests that the reduced EGFR inhibition
that occurred at the 100-mg dose compared with the 300-mg
dose allowed beneficial interaction between vandetinib’s
VEGFR inhibition and chemotherapy and that this beneficial
interaction was partially overcome by increased EGFR inhi-
bition at the 300-mg dose level. These observations are also
currently under investigation in a definitive, prospective,
randomized, double-blind, international clinical trial of do-
cetaxel combined with vandetinib, 100 mg daily, versus
docetaxel combined with placebo.
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